ODI Pharma

YEAR-END REPORT

July 2025 – June 2026

ODI Pharma Schweiz AG
Grafenauweg 8
6301 Zug
Switzerland

ODI Pharma AB
Östermalmstorg 1
114 42 Stockholm
Sweden

ODI Pharma Sp. z o.o.
Towarowa 28
00-839 Warschau
Poland

ODI PHARMA YEAR-END REPORT

In this year-end report, the following definitions apply, unless stated otherwise: The "Company" or "ODI Pharma" refers to ODI Pharma AB with org. number (Swedish corporate registration number) 559223-1392. Amount in brackets refers to the corresponding period in the previous year. ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.

Fourth quarter (2026-04-01 – 2026-06-30)

- The Group's net sales amounted to SEK 3,197,373 (6,461).
- The Group's profit after financial items amounted to SEK 153,040 (-1,660,970).
- Result per share amounted to SEK 0.01 (-0.09).*

Twelve months (2025-07-01 – 2026-06-30)

- The Group's net sales amounted to SEK 32,915,945 (3,133,879).
- The Group's profit after financial items amounted to SEK 1,987,683 (-5,929,115).
- Result per share amounted to SEK 0.11 (-0.35).*
- The solidity as of 2026-06-30 was 45% (9%).**

** The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30th of June 2026, amounted to 18,330,419 (18,330,419) shares. The result per share based on the average number of shares of 18,330,419 (16,784,210) amounts to SEK 0.11 (-0.35) for the twelve months 2025-07-01 to 2026-06-30.*
*** Solidity: Equity divided by total capital.*

Highlights during the fourth quarter

- Following solid operational cash flow in recent quarters, ODI Pharma repaid the remaining EUR 150,000 of its outstanding working capital loan in the beginning of June. ODI Pharma is now free of interest bearing debt and better positioned to focus on executing its growth strategy.

- A new commission-based contract through the Swiss subsidiary contributed to the net income of the company.

Highlights after the end of the period

- No significant events occurred after the end of the period.

MESSAGE FROM THE CHAIRMAN, VOLKER WIEDERRICH

The 2025/2026 financial year was a year of significant progress for ODI Pharma. We entered the year with a clear focus on strengthening our commercial position, increasing volumes in our core market and continuing to build a more stable and scalable business. Over the course of the year, we made important progress on all three fronts. Our position in Poland strengthened considerably, the business delivered substantially higher sales and, importantly, this commercial development was accompanied by a clear improvement in profitability.

Group net sales increased to SEK 32.9 million from SEK 3.1 million in the previous year, while profit after financial items improved to SEK 2.0 million from a loss of SEK 5.9 million. We also completed the year with four consecutive quarters of positive EBITDA and three consecutive quarters of positive net income. For us, this is an important indication that the progress made during the year is not only reflected in higher volumes, but also in the underlying financial development of the business.

Fourth-quarter revenues amounted to SEK 3.5 million, compared with SEK 12.8 million in the previous quarter and SEK 0.1 million in the corresponding quarter last year. The sequential decrease was primarily related to order timing, as our largest customer placed a larger order towards the end of Q3 and therefore required only one smaller order in Q4. Against the background of the strong full-year development, we do not view the lower Q4 sales level as an indication of weaker underlying demand.

During the quarter, the Swiss subsidiary also added a new customer under a commission-based arrangement. The contract contributed positively to both revenue and the Group’s net income. Due to the structure of the arrangement, ODI Pharma does not sell the underlying products directly, meaning that the value of those products is not reflected in reported net sales or cost of goods sold. The agreement therefore represents an additional source of earnings and broadens the ways in which we can utilize our existing network and market presence.

The Polish medical cannabis market continued to develop positively during the year. Following the disruption caused by regulatory changes introduced in late 2024, pharmacy dispensing volumes recovered and subsequently returned to record levels. ODI Pharma continued to strengthen its position and accounted for approximately 20% of total market supply during the year, compared with our original target of 10%. This development demonstrates the progress we have made in establishing ODI Pharma as a significant participant in our core market.

We also ended the year with a considerably stronger financial position. In June, the remaining EUR 150,000 of the working capital loan was repaid, leaving the Group free of interest-bearing debt. Together with the improved operating performance, this provides us with a stronger foundation for the continued development of the business.

Looking ahead, our main priority remains to consolidate and further strengthen our position in Poland. At the same time, the European medical cannabis market continues to evolve as regulatory frameworks and commercial conditions develop across several countries. France is expected to move towards a permanent medical cannabis framework following the completion of its pilot program, while developments are also taking place in other European markets. We continue to monitor these developments and assess where our existing business model and partnerships may provide opportunities over time.

We enter the new financial year from a stronger position than twelve months ago, with a larger commercial base, improved profitability and a strengthened balance sheet. Our focus remains on disciplined execution, sustainable growth and continuing to build long-term value for ODI Pharma and its shareholders.

Finally, I would like to thank our investors, partners and colleagues for their continued confidence and contribution during the year. We look forward to continuing the development of ODI Pharma in the year ahead.

Volker Wiederrich
Chairman of the Board, ODI Pharma AB

ABOUT ODI PHARMA

ODI Pharma aims to become a leading supplier of medical cannabis on the Company's target markets in Europe. The European market for medical cannabis has the potential to become the world's largest market for medical cannabis.

ODI Pharma was founded and is led by a team of professionals with long experience as doctors, researchers, investors, and corporate managers. The founders and board members of the Company have an extensive background in both trading and the medical cannabis industry.

ODI Pharma, based on its European network, subsidiaries, and partners, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. Z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. As this goal is coming to fruition, sights are being set for expansion to other markets.

ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals. The main focus of ODI Pharma is on the medical cannabis products that are sold to clients and patients through ODI Pharma's relationships with pharmacies via wholesale distributors.

In addition, ODI Pharma believes that CBD-infused cosmetics is thought to be a perfect complement to its pharmaceutical focus, allowing ODI Pharma to benefit from synergies and mutual benefits.

In August 2023, ODI Pharma successfully expanded its business relationship with the NEUCA group by signing an exclusive supply collaboration agreement covering not only Poland, but 23 countries in Eastern Europe. Further, the Company has a valuable supply contract with a wholly owned subsidiary of the largest cannabis producer in the world. The supplier is a first-tier producer who operates at the highest standards.

ODI Pharma believes that European clients require a wide variety of medical cannabis products of high quality to treat specific illnesses. The Company is a producer of finished pharmaceutical cannabis products and therefore has no cultivation operations but has access to a wide variety of different strains, oils, and the latest formulas. The Company intends to provide a range of medical cannabis products.

The products

Medical cannabis comes in a range of different products with different levels of THC (Tetrahydrocannabinol) and CBD (Cannabidiol). The products that ODI Pharma represent for the Polish market, per the *Polish Strategy,* are products that will be approved by the Polish governmental agencies.

Initially, the products will be dried flowers, since this is the product that this far has been regulated in Poland (even though the law in Poland allows for a range of derivates from the cannabis plant). These products are based on the raw material of fully approved cannabis imported by the Company and strategic partners. The dried flowers can be consumed by the patients in various ways following the guidelines of the pharmacists. ODI Pharma is evaluating other product types besides dried flowers to be sold on the Polish market.

ODI Pharma intends to be up to date on trends and regulatory requirements and future products may, therefore, differ from the current products. The market demand decides what type of medical cannabis products the Company will supply, which the Company's flexible business model enables. The production of the products is fully integrated with NEUCA. The current market price of dried flowers for patients in Poland is approx. EUR 7.00-15.00 (based on current exchange rate) per gram. Whatever product type of medical cannabis ODI Pharma provides; the objective is to be cost-efficient concerning what has previously been stated.

Target groups

There is a total of about 40+ indications in which medical cannabis may potentially show results in terms of efficacy.

Poland has an estimated 120,000 to 150,000 active medical cannabis patients, with industry data pointing to over 300,000 unique patients who have filled prescriptions over broader annual periods.

The patient base expanded rapidly through private telehealth networks before experiencing a temporary drop following stricter in-person examination rules for controlled substances introduced in late 2024.

The market fully rebounded from the regulatory changes, with Polish pharmacies dispensing record amounts of dried cannabis flower.

The Polish regulations do not limit the prescriptions for medical cannabis concerning certain ailments – therefore all physicians have the authorization to prescribe medical cannabis to all their patients and all types of illnesses. The Supreme Pharmaceutical Chamber of Poland suggested the application with treatable conditions including nausea caused by chemotherapy, epilepsy, symptoms of multiple sclerosis, and chronic pain.



Source: PP and Fakty Konopne

The import volume is a measure of supply, not consumption. The raw material imported in a given year may remain in the warehouse of a wholesaler or pharmacy into the next year, and some batches do not pass quality control and do not enter circulation at all. The import curve clearly shows the direction and order of magnitude, but it does not replace sales data, which are not centrally collected for non-reimbursed raw materials.

Market development

The European medical cannabis market continues to develop, with growing volumes accompanied by increasing competition and pricing pressure. Poland has shown a strong recovery following regulatory changes introduced in late 2024, with dispensing volumes subsequently returning to record levels. During the year, ODI Pharma continued to strengthen its position in the Polish market and accounted for approximately 20% of total market supply, significantly exceeding its previous target of 10%.

The development in Poland reflects continued underlying demand for medical cannabis. While the market experienced significant disruption following restrictions on telemedicine prescriptions, volumes recovered during 2025 and reached a new monthly high towards the end of the year. At the same time, increased competition has contributed to lower market prices, illustrating that continued volume growth does not necessarily translate into corresponding growth in market value.

Developments in the more mature German market further illustrate both the opportunities and challenges as European medical cannabis markets expand. Germany has experienced substantial volume growth, but this has been accompanied by significant price compression and increasing pressure on suppliers. The development highlights the importance of maintaining an efficient cost structure and a strong position within the distribution chain as markets mature.

France is expected to move towards a permanent medical cannabis framework following the completion of its pilot programme, although the timing and final structure remain subject to regulatory decisions. ODI Pharma continues to evaluate selected opportunities in France and other regulated European markets where its partner-led model may be applicable.

Looking ahead, ODI Pharma expects the European medical cannabis market to continue growing in volume, although regulatory developments and pricing pressure are likely to remain important factors. The Company believes that its established position in Poland, scalable business model and existing partnerships provide a solid foundation for continued growth as the market develops.

Source: European Cannabis Insights 2026, Business of Cannabis / Prohibition Partners

ABOUT THE YEAR-END REPORT

Group structure

ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG (100 %). ODI Pharma Schweiz AG has an ownership of 100 % in ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 (the "Group") when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.

Revenue and operating results Q4

The Group's revenue amounted to SEK 3,548,294 (149,711) in the fourth quarter and resulted in an operating income of SEK 149,228 (-1,522,215). Net sales decreased compared with the previous quarter, primarily due to order timing, as the Group's largest customer placed a larger order towards the end of Q3 and therefore only a smaller order in Q4. At the same time, the Swiss subsidiary added a new customer under a commission-based arrangement, which contributed positively to the Group's result while having a comparatively limited impact on net sales and cost of goods sold. The majority of the operating expenses are related to procurement of raw materials and products, salaries, insurance expenses, legal services, audit services, and accounting services. Personnel expenses increased during the year as compensation that had previously been waived was partially reinstated. The current personnel cost level is expected to remain broadly stable as sales grow. The holding company, ODI Pharma AB, has generated revenues of SEK 2,014,199 (-189,836) during the fourth quarter.

Balance sheet and solidity

ODI Pharma AB was registered with the Swedish Companies Registration Office on the 23rd of October 2019 with shareholder equity of SEK 500 000. The Company has no long-term liabilities. The group was established on the 28th of June 2018. Total assets of the Group amounted to SEK 5,301,292 (4,610,204) and consisted primarily of current receivables and cash and cash equivalents. The solidity of the Group was 45% (9%) at quarter-end. The holding company, ODI Pharma AB, stated total assets of SEK 3,602,079 (5,059,963) consisting primarily of receivables in group companies. The solidity of ODI Pharma AB was 40% (12%).

Cash flow and investments

Following strong operational cash flow in recent quarters, the Company repaid the remaining EUR 150,000 of its working capital loan during the fourth quarter and is now free of interest-bearing debt. Cash flow from operations in the Group during the fourth quarter amounted to SEK 364,191 (-2,084,107). Cash flow from financing and investment activities during the fourth quarter amounted to SEK -1,734,575 (2,001,701), resulting in cash flow from April 2026 to June 2026 of SEK -1,370,384 (-82,406). The holding company, ODI Pharma AB, showed a cash flow for the period (after financing and investment activity) of SEK -573,546 (-733,469) during the fourth quarter.

The share

The shares of ODI Pharma were listed on Spotlight Stock Market on the 23rd of January 2020. The short name/ticker is ODI and the ISIN code is SE0013409760. Spotlight Stock Market operates a so-called MTF platform under the supervision of the Swedish Financial Supervisory Authority. On the 30th of June 2026, the number of shares in ODI Pharma amounted to 18,330,419 (18,330,419). The average number of shares during the fourth quarter amounted to 18,330,419 (18,330,419). Every share equals the same rights to the Company´s assets and results.

Warrants

No warrants are outstanding to any party.

Financial calendar

July 2026 – September 2026 (Q1)	26th of November 2026

Proposal for disposition of ODI Pharma's results

The Board and the CEO propose that no dividend be paid for the financial year 2025-07-01 2026-06-30.

Annual General Meeting and availability of the Annual report

The Annual General Meeting will be held on December 4th, 2026, in Stockholm. The annual report will be available on the Company's website (www.odipharma.com) no later than three weeks before the Annual General Meeting.

Shareholders

The table below presents the current shareholders, as of 30th of June 2026, with more than 5 percent of the votes and capital in ODI Pharma AB.

Name	Number of shares	The proportion of votes and capital (%)
Volker Wiederrich	7,044,909	38.43
Niclas Kappelin	5,191,416	28.32
Derek Simmross	4,257,692	23.23
Other shareholders (approx. 1,000)	*1,836,402*	*10.02*
Total	**18,330,419**	**100.00**

Auditor's review

The year-end report has not been reviewed by the Company's auditor.

Accounting policy of the year-end report

The financial statements of ODI Pharma AB, as well as the ODI Pharma Group, are prepared per the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR) 2012:1 (K3) and Spotlight Stock Market's Rules and Regulations, as applicable. Consolidated accounts include parent company and subsidiaries in which the parent company directly or indirectly owns shares that are more than 50 % of the votes. Intangible and tangible assets are at the acquisition value reduced with accumulated depreciation according to plan and eventually write-downs. Depreciation is done linearly in relation to expected useful life. The financial overviews of ODI Pharma's subsidiaries were prepared in the local currency (CHF for the Swiss subsidiary and PLN for the Polish subsidiary). For this report, the local currencies have been recalculated to SEK in the financial overview, based on data from Sveriges Riksbank on the 30th of June 2026, respectively the average exchange rate for the presented time frame.

Common Control Transaction

During the financial year 2019/2020, ODI Pharma AB acquired ODI Pharma Schweiz AG from the previous owners through a related party transaction. The acquisition was carried out through a promissory note of CHF 100,000, which, in accordance with an established agreement, was subject to set-off in connection with a new issue using the K3 currency conversion principle. K3 does not comment on common control transactions and in the absence of guidance, the company has chosen to report the transaction based on the former group's book values, since the newly formed company is not considered an acquirer in the transaction. This means that ODI Pharma AB's consolidated accounts are a continuation of what was previously reported in the ODI Pharma Switzerland Group and the comparative figures presented are the ODI Pharma Switzerland Group's financial information for 2018, adjusted for differences in accounting principles.

Other operational risks and uncertainties

The risks and uncertainties that ODI Pharma’s operations are exposed to are summaries related to factors such as development, competition, permissions, capital requirements, customers, suppliers/manufacturers, currencies, and interest rates.

ODI Pharma’s operations require a solid cash and capital basis. The operations would face severe downside in case a solid basis is not sustained.

Submission of the year-end report

Stockholm, 27 of August 2026
ODI Pharma AB
The Board of Directors

For further information, please contact

Volker Wiederrich, Chairman
E-mail: info@odipharma.com
Website: https://www.odipharma.com/

ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018.

Income statement – the group

SEK	2026-04-01 2026-06-30 *3 months*	2025-04-01 2025-06-30 *3 months*	2025-07-01 2026-06-30 *12 months*	2024-07-01 2025-06-30 *12 months*
Revenue				
Net Sales	3,197,373	6,461	32,915,945	3,133,879
Other operating income	350,921	143,250	558,920	314,947
	3,548,294	**149,711**	**33,474,865**	**3,448,826**
Operating expenses				
Cost of goods sold	-1,514,504	-	-22,646,928	-2,294,815
External expenses	-678,446	-806,376	-3,934,367	-4,717,315
Personal expenses	-734,505	-784,987	-3,649,582	-1,394,156
Depreciation and amortization	-1,450	-491	-4,650	-1,972
Other operating expenses	-470,162	-80,071	-734,692	-491,725
Operating cost	**-3,399,066**	**-1,671,926**	**-30,970,219**	**-8,899,983**
Operating income	**149,228**	**-1,522,215**	**2,504,646**	**-5,451,157**
Profit/loss from financial items				
Other interest income and similar profit/loss items	72,691	24,832	85,915	263,051
Interest expense and similar profit/loss items	-68,878	-163,587	-602,877	-741,009
Income after financial items	**153,040**	**-1,660,970**	**1,987,683**	**-5,929,115**
Income before taxes	**153,040**	**-1,660,970**	**1,987,683**	**-5,929,115**
Taxes	-	-4,182	-24	-4,228
Net income	**153,040**	**-1,665,152**	**1,987,659**	**-5,933,343**
Number of shares in the beginning of the period	*18,330,419*	*18,330,419*	*18,330,419*	*15,220,000*
Number of shares at the end of the period	*18,330,419*	*18,330,419*	*18,330,419*	*18,330,419*
Average number of shares	*18,330,419*	*18,330,419*	*18,330,419*	*16,784,210*
Earnings per share, SEK	*0.01*	*-0.09*	*0.11*	*-0.35*

Balance Sheet – the group

SEK	2026-06-30	2025-06-30
Assets		
Fixed assets		
Subscribed but unpaid capital	-	1,000,000
Tangible fixed assets		
Equipment, machines, tools	10,998	4,484
	10,998	1,004,484
Total fixed assets	**10,998**	**1,004,484**
Current assets		
Inventories		
Raw materials and consumables	-	-
Finished goods and goods for resale	-	-
Advance payments to supplier	-	-
	-	**-**
Current receivables		
Trade receivables	180,642	115,582
Tax receivables	-	-
Other current receivables	862,203	1,377,494
Prepaid expenses and accrued income	859,722	628,604
	1,902,567	**2,121,680**
Cash and cash equivalents	3,387,727	1,484,040
Total current assets	**5,290,294**	**3,605,720**
TOTAL ASSETS	**5,301,292**	**4,610,204**

Balance Sheet – the group

SEK	2026-06-30	2025-06-30
EQUITY AND LIABILITIES		
Equity		
Share capital	733,216	636,601
Non-registered capital	-	96,615
Other contributed capital	27,076,016	25,957,080
Other equity including result for the period	-25,433,894	-26,265,652
Equity attributed to shareholders in parent company	**2,375,339**	**424,644**
Current liabilities		
Account payables	1,768,421	388,498
Tax liabilities	-	4,186
Other current liabilities	327,861	2,786,625
Accrued expenses and prepaid income	829,671	1,006,251
Total current liabilities	**2,925,953**	**4,185,560**
TOTAL EQUITY AND LIABILITIES	**5,301,292**	**4,610,204**

Cash flow statement – the group

SEK	2026-04-01 2026-06-30 *3 months*	2025-04-01 2025-06-30 *3 months*	2025-07-01 2026-06-30 *12 months*	2024-07-01 2025-06-30 *12 months*
Operating activities				
Net operating profit/loss	145,425	-1,523,731	2,503,514	-5,451,157
Non-cash affecting share issue	-	-	-	1,001,700
Adjustment for non-cash flow items				
Depreciations and write-downs	1,440	-	4,650	1,963
Current exchange differences	-	-	-	-23,585
Other items not affecting cash flow	-	-	-	-
Cash flow from operating activities	**146,865**	**-1,523,731**	**2,508,164**	**-4,471,079**
Received interest	1	-21,470	1,591	30,934
Paid interest	-64,398	-142,153	-573,012	-680,562
Paid tax	-	-4,201	-4,166	92,838
Cash flow from operation before change in working capital	**82,468**	**-1,691,555**	**1,932,577**	**-5,027,869**
Cash flow from change in working capital				
Change in inventories and ongoing works	-	-	-	-
Increase (-) Decrease (+) of operating receivables	4,797,892	1,681,134	1,434,630	9,978,197
Increase (+) Decrease (-) of operating liabilities	-4,516,169	-2,073,687	1,208,866	-8,256,172
Total change in working capital	**281,273**	**-392,552**	**2,643,496**	**1,722,025**
Cash flow from operating activities	**364,191**	**-2,084,107**	**4,576,073**	**-3,305,844**
Investment activities				
Investments in tangible fixed assets	-	-	-	-
Cash flow from investment activities	-	-	-	-
Financing activities				
Long-term borrowings	-1,734,575	-	-2,786,625	-
New share issue	-	2,001,701	-	2,238,009
New share issue expenses	-	-	-	-
Cash flow from financing activities	-1,734,575	2,001,701	-2,786,625	2,238,009
Cash flow for the period	**-1,370,384**	**-82,406**	**1,789,448**	**-1,067,835**
Cash and cash equivalents at beginning of year	4,149,694	1,944,240	1,488,644	2,643,931
Effects of exchange rate changes on cash	608,417	-377,794	109,635	-92,056
Cash and cash equivalents at end of year	**3,387,727**	**1,484,040**	**3,387,727**	**1,484,040**

Income statement – ODI Pharma AB

SEK	2026-04-01 2026-06-30 *3 months*	2025-04-01 2025-06-30 *3 months*	2025-07-01 2026-06-30 *12 months*	2024-07-01 2025-06-30 *12 months*
Revenue				
Net sales	1,730,565	-248,976	8,046,566	1,320,556
Other operating income	283,634	59,140	336,298	197,226
	2,014,199	**-189,836**	**8,382,864**	**1,517,782**
Operating expenses				
Cost of goods sold	-	-	-	-
External expenses	-436,120	-673,901	-3,014,628	-3,249,163
Personal expenses	-733,126	-784,987	-3,605,924	-1,355,433
Depreciation and amortisation	-	-	-	-
Other operating expenses	-40,116	-20,082	-413,893	-472,388
Total operating cost	**-1,209,362**	**-1,478,970**	**-7,034,445**	**-5,076,984**
Operating income	**804,837**	**-1,668,806**	**1,348,419**	**-3,559,202**
Income from financial items				
Anticipated dividend	-	-	-	-
Other interest income and similar profit/loss items	70,551	-	72,141	195,884
Interest expense and similar profit/loss items	-63,375	-142,153	-571,871	-672,840
Income after financial items	**812,013**	**-1,810,959**	**848,689**	**-4,036,158**
Income before taxes	**812,013**	**-1,810,959**	**848,689**	**-4,036,158**
Taxes	-	-	-	-
Net income	**812,013**	**-1,810,959**	**848,689**	**-4,036,158**
Number of shares in the beginning of the period	*18,330,419*	*18,330,419*	*18,330,419*	*15,220,000*
Number of shares at the end of the period	*18,330,419*	*18,330,419*	*18,330,419*	*18,330,419*
Average number of shares	*18,330,419*	*18,330,419*	*18,330,419*	*16,784,210*
Earnings per share, SEK	*0.04*	*-0.10*	*0.05*	*-0.24*

Balance Sheet – ODI Pharma AB

SEK	2026-06-30	2025-06-30
ASSETS		
Fixed assets		
Subscribed but unpaid capital	-	1,000,000
Financial fixed assets		
Loan group companies	-	-
Participations in groups companies	967,200	967,200
	967,200	**1,967,200**
Total fixed assets	**967,200**	**1,967,200**
Current assets		
Inventories		
Raw materials and consumables	-	-
Finished goods and goods for resale	-	-
Advance payments to suppliers	-	-
	-	**-**
Current receivables		
Trade receivables	-	-
Receivables in group companies	569,830	1,370,386
Other current receivables	767,724	1,259,295
Prepaid expenses and accrued income	569,720	252,924
	1,907,274	**2,882,605**
Cash and cash equivalents	727,605	210,158
Total current assets	**2,634,879**	**3,092,763**
TOTAL ASSETS	**3,602,079**	**5,059,963**

Balance Sheet – ODI Pharma AB

SEK	2026-06-30	2025-06-30
EQUITY AND LIABILITIES		
Equity		
Restricted reserves		
Share capital	733,216	636,601
Non-registered capital	-	96,615
Non-restricted reserves		
Share premium reserve		
Share premium	25,587,560	25,587,560
Retained earnings	-25,711,115	-21,674,958
Profit or loss for period	848,689	-4,036,157
Total equity	**1,458,350**	**609,661**
Current liabilities		
Account payables	283,943	239,855
Liabilities to group companies	1,016,653	720,627
Other current liabilities	327,861	2,786,625
Accrued expenses and prepaid income	515,272	703,195
Total current liabilities	**2,143,729**	**4,450,302**
TOTAL EQUITY AND LIABILITIES	**3,602,079**	**5,059,963**

Cash flow statement – ODI Pharma AB

SEK	2026-04-01 2026-06-30 *3 months*	2025-04-01 2025-06-30 *3 months*	2025-07-01 2026-06-30 *12 months*	2024-07-01 2025-06-30 *12 months*
Operating activities				
Net operating profit/loss	804,837	-1,668,806	1,348,419	-3,559,201
Non-cash affecting share issue	-	-	-	1,001,700
Adjustment for non-cash flow items				
Depreciations and write-downs	-	-	-	-
Current exchange differences	-	-	-	-
Other items not affecting cash flow	-	-	-	-
Cash flow from operating activities	**804,837**	**-1,668,806**	**1,348,419**	**-2,557,501**
Received interest	1	-	1,591	**30,934**
Paid interest	-58,933	-142,153	-567,429	-672,840
Paid tax	-	-	-	-
Cash flow before change in working capital	**745,905**	**-1,810,959**	**782,581**	**-3,199,407**
Cash flow from change in working capital				
Change in inventories and ongoing works	-	-	-	-
Increase (-) Decrease (+) of operating receivables	-419,178	-1,702,197	1,975,331	1,036,654
Increase (+) Decrease (-) of operating liabilities	834,302	777,986	480,052	-1,965,906
Total change in working capital	**415,124**	**-924,211**	**2,455,383**	**-929,252**
Cash flow from operating activities	**1,161,029**	**-2,735,170**	**3,237,964**	**-4,128,659**
Investment activities				
Investments	-	-	-	-
Cash flow from investment activities	-	-	-	-
Investing activities				
Loan	-	-	-	-
Cash flow from investing activities	-	-	-	-
Financing activities				
Long-term borrowings	-1,734,575	-	-2,786,625	-
Anticipated dividend	-	-	-	-
New shares issue	-	2,001,701	-	2,238,009
New share issue expenses	-	-	-	-
Cash flow from financing activities	**-1,734,575**	**2,001,701**	**-2,786,625**	**2,238,009**
Cash flow for the period	**-573,546**	**-733,469**	**451,339**	**-1,890,650**
Cash and cash equivalents at the beginning of year	1,236,540	943,627	210,158	1,935,858
Effects of exchange rate changes on cash	64,612	-	66,108	164,950
Cash and cash equivalents at the end of year	**727,605**	**210,158**	**727,605**	**210,158**


ODI Pharma